{"slideshow_credits": null, "snippet": "As an advisory panel prepared to consider whether to recommend federal approval of Pfizer\u2019s rheumatoid arthritis pill, F.D.A. documents raise safety questions.", "abstract": "Food and Drug Administration says an experimental pill being developed by Pfizer to treat rheumatoid arthritis raises 'serious safety concerns' and is linked to a higher risk for lymphoma and serious infections. Photo (M)d", "section_name": "Health", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS"}, "web_url": "http://www.nytimes.com/2012/05/08/health/fda-staff-raises-concerns-about-arthritis-drug.html", "lead_paragraph": "Federal regulators said Monday that an experimental pill being developed by Pfizer to treat rheumatoid arthritis raised ''serious safety concerns'' and was linked to a higher risk for lymphoma, a form of cancer, and serious infections. Pfizer has identified the drug, known as tofacitinib, as one of the most promising and lucrative prospects in its drug pipeline. The company is struggling to regain lost sales after its best-selling cholesterol drug, Lipitor, lost patent protection last fall.", "headline": {"main": "F.D.A. Staff Raises Concerns About Arthritis Drug"}, "_id": "4fd2a9998eb7c8105d895065", "word_count": 541, "multimedia": [], "pub_date": "2012-05-07T00:00:00Z", "source": "The New York Times", "news_desk": "Health", "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "RHEUMATOID ARTHRITIS"}], "blog": [], "subsection_name": null, "type_of_material": "News"}